Jehanzeb Noor compensation by year
ZIMMER BIOMET Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $683,000 |
| Bonus | $1,115,509 |
| Stock awards | $5,100,212 |
| Option awards | $0 |
| Non-equity incentive | $730,913 |
| Pension and deferred compensation | $217,165 |
| All other | $27,409 |
| Total | $7,874,209 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ZIMMER BIOMET HOLDINGS, INC. DEF 14A filed April 1, 2026, accession 0001193125-26-135661, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ZIMMER BIOMET HOLDINGS, INC. filed document, accession 0001193125-26-135661. Every figure is read from that document and cited to the page and table it appears in. Filed April 1, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 18,212 | $1,637,623 | — |
| RSU | 11,744 | $1,056,020 | — |
| RSU | 8,131 | $731,140 | — |
| PSU | 7,988 | $718,281 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in ZIMMER BIOMET HOLDINGS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed April 1, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-01 | Grant or award derivative | — | 1,857 | $0.00 | 1,857 |
| 2026-04-01 | Exercise or conversion | — | 6,626 | $0.00 | 6,828 |
| 2026-04-01 | Tax withholding | — | 1,677 | $90.67 | 5,151 |
| 2026-04-01 | Exercise or conversion derivative | — | 6,626 | $0.00 | 13,249 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments ZIMMER BIOMET discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Retirement | $0 | $0 | $0 | $217,165 |
| Change in control and resignation for good reason | $1,660,629 | $5,425,529 | $13,705 | — |
| Voluntary resignation | $0 | $0 | $0 | $170,034 |
| Disability | $0 | $0 | $0 | $170,034 |
| Death | $0 | $0 | $0 | $170,034 |
| Change in control and involuntary termination | $3,072,163 | $5,425,529 | $13,705 | — |
| Involuntary for cause | $0 | $0 | $0 | $170,034 |
| Involuntary termination without cause | $2,241,848 | $0 | $0 | — |
Per the Potential Payments Upon Termination or Change in Control table in ZIMMER BIOMET HOLDINGS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
ZIMMER BIOMET’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ivan Tornos | Chairman, President and Chief Executive Officer | $16,106,550 |
| Jehanzeb Noor · this page | Senior Vice President, Chief Strategy, Business Development, Innovation and Transformation Officer | $7,874,209 |
| Suketu Upadhyay | Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain | $6,211,805 |
| Kevin Thornal | Group President, Global Businesses and the Americas | $6,210,746 |
| Wilfred van Zuilen | Group President, Europe, Middle East and Africa (EMEA) | $4,139,409 |
Jehanzeb Noor's compensation dossier, ZIMMER BIOMET
You have read Jehanzeb Noor's totals and holdings. The dossier adds each equity grant ZIMMER BIOMET disclosed for Jehanzeb Noor and ZIMMER BIOMET's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ZIMMER BIOMET compensation record
free company briefThis page is one person within ZIMMER BIOMET's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ZIMMER BIOMET proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ZIMMER BIOMET's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ZIMMER BIOMET's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ZBH
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.